top of page
ERC logo.png

StG-MTrix

ERC logo.png

POC-EmboPore

ERC logo.png

POC-HybridNP

MTrix project

Targeted drug delivery is key to balancing efficacy and safety, especially in oncology, where chemotherapy’s poor selectivity causes severe side effects. Tumor heterogeneity complicates the identification of universal targets. In this ERC-funded project, we demonstrated how nanocarriers can be tailored using Mechanical Targeting, exploiting cancer cells' deformability. Since metastatic cells are more flexible, they preferentially internalize particles requiring shape adaptation, unlike rigid normal cells. By integrating experimental and computational models, we enable personalized DDS, optimizing drug uptake based on patient-specific cell mechanics, advancing precision nanomedicine.

Science Avances yifat.PNG
Science Advance Yoel.PNG
MTRIX1.JPG

HybridNP

Precisely controlling drug release at specific body sites remains a major challenge in drug delivery. By leveraging remotely controlled nanomaterials, we can now direct drug carriers to target tissues while simultaneously modulating their shape to enhance effectiveness. Smart hybrid materials, combining organic compounds and metals, offer a versatile, multi-functional approach for treating cancer.

ACS nano.PNG
ACS Health.PNG
nn2c05733_alt_cover_hires.jpg

EmboPore.

Embolization is a therapeutic strategy used to block blood flow for treating liver tumors. However, acute vascular obstruction significantly limits drug perfusion into the tumor, reducing treatment efficacy. Moreover, adverse pro-angiogenic feedback contributes to the high recurrence rate of the disease. To address these challenges, we developed Drug-Eluting Porous Embolic Microspheres for trans-arterial delivery of a dual synergistic anticancer therapy for liver cancer. This innovative approach demonstrates how localized drug release and embolization can work synergistically to enhance treatment outcomes.

Embo paper.PNG
Cover Benzi 2023_edited.jpg
bottom of page